GEP testing to identify patients likely to benefit from ART therapy

DecisionDx-SCC provides an independent risk of metastasis score as well as identifies patients likely to benefit from adjuvant radiation therapy (ART).

Independently validated to predict ART treatment benefit

DecisionDx-SCC has now been independently validated to predict ART treatment benefit in two studies comprising over 1,300 patients. Together, these two studies by Ruiz et al. in Future Oncology (2024) and Arron et al. in the Red Journal (2024) represent the largest published population of ART-treated high-risk SCC patients. Results from this study provide a validation of the performance of the previously reported (Arron et al. Red Journal 2024) benefit of ART for Class 2B tumors and a lack of benefit for Class 1 tumors and was conducted using 423 tumors from 399 patients from Brigham Women’s Health (BWH) and Cleveland Clinic. Given the consistency of the results from two independent cohorts, DecisionDx-SCC can aid in ART decision-making for patients with high-risk SCC tumors.

Hear from an expert

Discover how Radiation Oncologist, Ramesh Gopal, MD, PhD, integrates the DecisionDx-SCC test into his practice

Want to learn more about DecisionDx-SCC?